ER-negative and HER2-positive rate was significantly higher during the pandemic [72], and delayed neoadjuvant therapy caused disease progression and delayed surgery may be associated with worsened BC, such as lesions [74]. This evidence concerns the gene ERBB2 and breast cancer.